Intensity Therapeutics, Inc.INTSNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank58
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P58
Within normal range
vs 2Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 0.78% |
| Q2 2025 | -29.60% |
| Q1 2025 | 11.29% |
| Q4 2024 | -8.55% |
| Q3 2024 | -39.63% |
| Q2 2024 | 26.57% |
| Q1 2024 | 56.28% |
| Q4 2023 | 33.23% |
| Q3 2023 | 57.35% |
| Q2 2023 | 11.04% |
| Q1 2023 | -13.17% |
| Q4 2022 | -23.23% |
| Q3 2022 | -16.25% |
| Q2 2022 | -18.21% |
| Q1 2022 | 17.87% |
| Q4 2021 | -4.06% |
| Q3 2021 | -12.05% |
| Q2 2021 | 40.00% |
| Q1 2021 | -13.50% |
| Q4 2020 | 0.00% |